IL2 and chronic graft versus host disease: Recently, it was reported that low-dose IL-2 can selectively stimulate and expand Tregs, which are beneficial in facilitating recovery for patients with autoimmune diseases such as T1D, rheumatoid arthritis, and systemic lupus erythematosus, as well as other diseases such as HCV-induced vasculitis and chronic GVHD 23, 26, 53, 54.